Factor VIII Antibody (RFFVIII C/5)

Product Discontinued

Factor VIII Antibody (RFFVIII C/5) Summary

• Immunogen: Made to Human FACTOR VIII
• Localization: Secreted
• Specificity: Detects the 360 kDa band of human factor VIII as well as the 80 kDa doublet bands. This cross reacts with porcine Factor VIII. There is no cross reactivity with von Willebrand factor.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: F8
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot 1:100-1:2000
• Application Notes: WB: Use at a dilution of 1/25 - 1/200. Not tested in other applications. Optimal dilutions should be determined by the end user.

Reactivity Notes

Cross-reacts with Human. Not yet tested in other species.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS and 50% Glycerol
• Preservative: No Preservative
• Concentration: 0.5 mg/ml
• Purity: Protein A or G purified

Alternate Names for Factor VIII Antibody (RFFVIII C/5)

• AHF
• Antihemophilic factor
• coagulation factor VIII, procoagulant component
• coagulation factor VIIIc
• DXS1253E
• F8Ccoagulation factor VIII
• factor VIII F8B
• FVIII
• HEMAF8B
• Procoagulant component

Background

Factor VIII, along with calcium and phospholipid, acts as a cofactor for factor IXa when it converts factor X to the activated form, factor Xa. It is an extracellular factor. Defects in F8 are the cause of hemophilia A (HEMA). HEMA is a common recessive X linked coagulation disorder. The frequency of hemophilia A is 1-2 in 10,000 male births in all ethnic groups. About 50% of patients have severe hemophilia A with F8C activity less than 1% of normal; they have frequent spontaneous bleeding into joints, muscles and internal organs. Moderately severe hemophilia A occurs in about 10% of patients; F8C activity is 2-5% of normal, and there is bleeding after minor trauma. Mild hemophilia A, which occurs in 30-40% of patients, is associated with F8C activity of 5-30% and bleeding occurs only after significant trauma or surgery. Of particular interest for the understanding of the function of F8C is the category of CRM (cross-reacting material) positive patients (approximately 5%) that have considerable amount of F8C in their plasma (at least 30% of normal), but the protein is nonfunctional; i.e., the F8C activity is much less than the plasma protein level. CRM reduced is another category of patients in which the F8C antigen and activity are reduced to approximately the same level. Most mutations are CRM negative, and probably affect the folding and stability of the protein.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: F8
• Entrez:
  • 2157(Human)
• Uniprot:
  • P00451(Human)